BRAF and non-small cell lung carcinoma: In a Phase Ib upgrade/expansion study, LXH254 was evaluated in conjunction with trametinib among patients grappling with advanced/metastatic non-small cell lung cancer harboring KRAS or BRAF mutations and NRAS-mutated melanoma (NCT02974725).